From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus

References

• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-68
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Tomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci 2002;967:43-51
   PubMed Web of Science ®Google Scholar
• Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-12
   PubMed Web of Science ®Google Scholar
• Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003;16:5-22
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Fox KM, Gerber RA, Bolinder B, et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95
   PubMed Web of Science ®Google Scholar
• Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, et al. Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. J Med Assoc Thai 2006;89(Suppl 1):S66-71
   PubMedGoogle Scholar
• Suh DC, Kim CM, Choi IS, et al. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc 2008;56:484-92
   PubMed Web of Science ®Google Scholar
• Grant RW, Cagliero E, Dubey AK, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med 2004;21:150-5
   PubMed Web of Science ®Google Scholar
• Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007;30:807-12
   PubMed Web of Science ®Google Scholar
• Duckworth W. Glycemic control and cardiovascular outcomes - the VA Diabetes Trial. (Abstract) 68th Annual Meeting of the American Diabetes Association, June 6-10, 2008; San Francisco, CA
   Google Scholar
• Bays HE. ‘Sick fat,” metabolic disease, and atherosclerosis. Am J Med 2009;122 (Suppl 1):S26-S37
   PubMed Web of Science ®Google Scholar
• Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998;102:619-24
   PubMed Web of Science ®Google Scholar
• Gerich JE, Meyer C, Woerle HJ, et al. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001;24:382-91
   PubMed Web of Science ®Google Scholar
• Meyer C, Dostou JM, Welle SL, et al. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002;282:E419-27
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-18
   PubMed Web of Science ®Google Scholar
• Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003;89:3-9
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43
   PubMed Web of Science ®Google Scholar
• Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004;447:510-18
   PubMed Web of Science ®Google Scholar
• Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 2000;23:237-46
   PubMed Web of Science ®Google Scholar
• Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007;106:S27-35
   PubMed Web of Science ®Google Scholar
• Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74:993-1026
   PubMed Web of Science ®Google Scholar
• Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Brenner B, ed. Brenner and Rector's The Kidney. 8th edn, Vol 1. Philadelphia, PA: Saunders, 2008
   Google Scholar
• Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-9
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-34
   PubMed Web of Science ®Google Scholar
• Tazawa S, Yamato T, Fujikura H, et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005;76:1039-50
   PubMed Web of Science ®Google Scholar
• Chen J, Feder J, Neuhaus I, et al. Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: implication for targeting SGLT2 in type 2 diabetes patients. (Abstract) 68th Annual Meeting of the American Diabetes Association, June 6-10, 2008; San Francisco, CA
   Google Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8
   PubMed Web of Science ®Google Scholar
• Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 2004;19:2394-6
   PubMed Web of Science ®Google Scholar
• Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82
   PubMed Web of Science ®Google Scholar
• Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-15
   PubMed Web of Science ®Google Scholar
• Blondel O, Bailbe D, Portha B. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism 1990;39:787-93
   PubMed Web of Science ®Google Scholar
• Kahn BB, Shulman GI, DeFronzo RA, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991;87:561-70
   PubMed Web of Science ®Google Scholar
• Kim YW, Kim JY, Lee SK. Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats. J Korean Med Sci 1995;10:24-30
   PubMedGoogle Scholar
• Simonson GD, Kendall DM. Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. Coron Artery Dis 2005;16:465-72
   PubMed Web of Science ®Google Scholar
• Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47:201-10
   PubMed Web of Science ®Google Scholar
• Wright EM. I. Glucose galactose malabsorption. Am J Physiol 1998;275(5 Pt 1):G879-82
   Web of Science ®Google Scholar
• Booth AN, Jones FT, Deeds F. Metabolic and glucosuria studies on naringin and phloridzin. J Biol Chem 1958;233:280-2
   PubMed Web of Science ®Google Scholar
• De Jonge PC, Wieringa T, Van Putten JP, et al. Phloretin - an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1983;722:219-25
   PubMed Web of Science ®Google Scholar
• Tsujihara K, Hongu M, Saito K, et al. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 1996;44:1174-80
   Google Scholar
• Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-800
   PubMed Web of Science ®Google Scholar
• Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8:285-92
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-9
   PubMed Web of Science ®Google Scholar
• Glombik H, Frick W, Heuer H, et al. Synthesis and therapeutic evaluation of thiophene glycosides for the use in treatment of diabetes or for lowering blood sugar levels. Chem Abstr 2004;140 (PCT Int Appl. WO2004007517)
   Google Scholar
• Washburn W, Sher P, Wu G. Preparation of O-aryl glucosides as antidiabetic agents and SGLT2 inhibitors. Chem Abstr 2001;135 (U.S. Patent 6683056)
   Google Scholar
• Washburn W. Preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents. Chem Abstr 2003;138 (PCT Int. Appl. WO/2003/020737.)
   Google Scholar
• Hussey E, Clark R, Amin DM, et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. (Abstract 189-OR) 67th Annual Meeting of the American Diabetes Association, June 22-26, 2007; Chicago, IL
   Google Scholar
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 Jan 7. [Epub ahead of print]
   Google Scholar
• Leslie B, Tang W, List J. Renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (BMS-512148) in patients with type 2 diabetes mellitus (T2DM). American Society of Nephrology Renal Week, November 2008
   Google Scholar
• Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005;5:275-86
   PubMed Web of Science ®Google Scholar
• Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
   PubMedGoogle Scholar
• Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-42
   PubMed Web of Science ®Google Scholar
• Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004: CD003418
   PubMedGoogle Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63
   PubMed Web of Science ®Google Scholar